Shady M Abd El-Halim1, Ghada A Abdelbary2, Maha M Amin2, Mohamed Y Zakaria3, Hesham A Shamsel-Din4, Ahmed B Ibrahim4. 1. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Central Axis, 6th of October City, Giza, 12585, Egypt. shady_mohammed@o6u.edu.eg. 2. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt. 3. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy and Pharmaceutical Industry, Port Said University, Port said, 42526, Egypt. 4. Department of Labeled Compounds, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt.
Abstract
PURPOSE: Adefovir dipivoxil (AD), a nucleoside reverse transcriptase inhibitor is effective against Hepatitis B virus. Its poor oral bioavailability leads to frequent administration causing severe adverse effects. Thereby the entrapment of AD within lipid nanoparticulate systems is a way of increasing AD oral bioavailability as a result of improving intestinal permeability with efficient liver-targeted delivery together with higher drug stability during storage. METHODS: AD-loaded nanostructured lipid carriers (AD-NLCs) were prepared via solvent emulsification diffusion technique adopting 24 full factorial design to study the effect of lipid percentage, presence of egg yolk lecithin, surfactant type and percentage on entrapment efficiency (E.E.%), particle size and percent in-vitro drug released after 8 h (Q8hrs). RESULTS: Formula (F12) showed E.E.% of 90.5 ± 0.2%, vesicle size of 240.2 ± 2.5 nm and Q8hrs of 58.55 ± 9.4% was selected as the optimum formula with desirability value of 0.757 based on highest EE%, lowest P.S. and Q8hrs. Further evaluation of the optimized formula using radioiodinated rose bengal (RIRB) in thioacetamide induced liver damage in Swiss Albino mice revealed a higher liver uptake of 22 ± 0.01% ID/g (percent injected dose/g organ) and liver uptake/Blood (T/B) ratio of 2.22 ± 0.067 post 2 h of I.V injection of RIRB compared to 9 ± 0.01% ID/g and 0.64 ± 0.017 in untreated group, respectively. CONCLUSION: NLCs could be successfully used as oral drug delivery carriers of the antiviral drug Adefovir Dipivoxil to the liver with higher stability and oral bioavailability. Graphical abstract.
PURPOSE:Adefovir dipivoxil (AD), a nucleoside reverse transcriptase inhibitor is effective against Hepatitis B virus. Its poor oral bioavailability leads to frequent administration causing severe adverse effects. Thereby the entrapment of AD within lipid nanoparticulate systems is a way of increasing AD oral bioavailability as a result of improving intestinal permeability with efficient liver-targeted delivery together with higher drug stability during storage. METHODS:AD-loaded nanostructured lipid carriers (AD-NLCs) were prepared via solvent emulsification diffusion technique adopting 24 full factorial design to study the effect of lipid percentage, presence of egg yolk lecithin, surfactant type and percentage on entrapment efficiency (E.E.%), particle size and percent in-vitro drug released after 8 h (Q8hrs). RESULTS: Formula (F12) showed E.E.% of 90.5 ± 0.2%, vesicle size of 240.2 ± 2.5 nm and Q8hrs of 58.55 ± 9.4% was selected as the optimum formula with desirability value of 0.757 based on highest EE%, lowest P.S. and Q8hrs. Further evaluation of the optimized formula using radioiodinated rose bengal (RIRB) in thioacetamide induced liver damage in Swiss Albino mice revealed a higher liver uptake of 22 ± 0.01% ID/g (percent injected dose/g organ) and liver uptake/Blood (T/B) ratio of 2.22 ± 0.067 post 2 h of I.V injection of RIRB compared to 9 ± 0.01% ID/g and 0.64 ± 0.017 in untreated group, respectively. CONCLUSION: NLCs could be successfully used as oral drug delivery carriers of the antiviral drug Adefovir Dipivoxil to the liver with higher stability and oral bioavailability. Graphical abstract.
Authors: Doaa Ahmed El-Setouhy; A B Ibrahim; Maha M Amin; Omneya M Khowessah; Eman S Elzanfaly Journal: Eur J Pharm Sci Date: 2016-05-03 Impact factor: 4.384
Authors: Samia A Nour; Nevine S Abdelmalak; Marianne J Naguib; Hassan M Rashed; Ahmed B Ibrahim Journal: Drug Deliv Date: 2016-09-20 Impact factor: 6.419
Authors: Syed Nasir Abbas Bukhari; Mohamed Y Zakaria; Muhammad Usman Munir; Naveed Ahmad; Mervat A Elsherif; Rasha Emad Badr; Ahmad Khalaf Hassan; Ali H Abu Almaaty; Islam Zaki Journal: Pharmaceuticals (Basel) Date: 2022-05-28
Authors: Sara M Soliman; Shaimaa Mosallam; Mohamed A Mamdouh; Mohammed Abdalla Hussein; Shady M Abd El-Halim Journal: Drug Deliv Date: 2022-12 Impact factor: 6.419
Authors: Islam Zaki; Amal M Y Moustafa; Botros Y Beshay; Reham E Masoud; Mohammed A I Elbastawesy; Mohammed A S Abourehab; Mohamed Y Zakaria Journal: J Enzyme Inhib Med Chem Date: 2022-12 Impact factor: 5.756
Authors: Mohamed Y Zakaria; Islam Zaki; Majid Alhomrani; Abdulhakeem S Alamri; Osama Abdulaziz; Mohammed A S Abourehab Journal: Drug Deliv Date: 2022-12 Impact factor: 6.819